- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
23 result(s) found for: Cyclin D.
Displaying page 1 of 2.
EudraCT Number: 2015-003892-31 | Sponsor Protocol Number: MedOPP089 | Start Date*: 2017-03-23 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
Full Title: A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combina... | |||||||||||||
Medical condition: Patients with hormone receptor (HR)-positive/HER2-negative locally advanced or metastatic breast cancer (mBC). Second/third-line of endocrine treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001965-41 | Sponsor Protocol Number: BRD/06/052 | Start Date*: 2008-09-05 |
Sponsor Name:University College London | ||
Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma | ||
Medical condition: Mantle Cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001521-41 | Sponsor Protocol Number: UoL001304 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002162-21 | Sponsor Protocol Number: JECF-VITD-2011-01 | Start Date*: 2012-04-24 |
Sponsor Name:José Esteban Castelao Fernández | ||
Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer. | ||
Medical condition: Women at high risk of developing breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006177-32 | Sponsor Protocol Number: CC-5013-MCL-003 | Start Date*: 2010-01-06 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA | |||||||||||||
Medical condition: Mantle-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) FR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005057-36 | Sponsor Protocol Number: GLG-801-07 | Start Date*: 2018-05-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GLG Pharma S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003435-13 | Sponsor Protocol Number: MARLENE | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer | |||||||||||||
Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000548-33 | Sponsor Protocol Number: LyMa101 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000157-41 | Sponsor Protocol Number: UoL001343 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:The University of Liverpool | |||||||||||||
Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj... | |||||||||||||
Medical condition: ER-positive, HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002324-36 | Sponsor Protocol Number: MK1026-003 | Start Date*: 2021-03-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies | |||||||||||||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) CZ (Trial now transitioned) HU (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002821-39 | Sponsor Protocol Number: MCLA-128-CL02 | Start Date*: 2017-11-13 | |||||||||||
Sponsor Name:Merus N.V. | |||||||||||||
Full Title: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive a... | |||||||||||||
Medical condition: Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004039-30 | Sponsor Protocol Number: MCL5(MARiT) | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:PLymouth Hospitals NHS Trust | |||||||||||||
Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002077-21 | Sponsor Protocol Number: ICR-CTSU/2017/10065 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005591-35 | Sponsor Protocol Number: INCMOR0208-101 | Start Date*: 2021-06-30 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibito... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) ES (Temporarily Halted) AT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005317-68 | Sponsor Protocol Number: ACE-CL-208 | Start Date*: 2016-05-16 | |||||||||||
Sponsor Name:Acerta Pharma B.V. | |||||||||||||
Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | |||||||||||||
Medical condition: High Risk Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001547-25 | Sponsor Protocol Number: ZILO-301 | Start Date*: 2023-04-04 | |||||||||||||||||||||
Sponsor Name:Oncternal Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma... | |||||||||||||||||||||||
Medical condition: Relapsed or Refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001648-24 | Sponsor Protocol Number: MedOPP321_ABIGAIL | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L. | |||||||||||||
Full Title: randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as f... | |||||||||||||
Medical condition: Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease crite... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004718-90 | Sponsor Protocol Number: UTX-TGR-205 | Start Date*: 2017-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:TG Therapeutics | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Ho... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Non-Hodgkin lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.